SCHEMBL3767973

SCHEMBL3767973

O=C(CN1CCN(c2cnc(-c3cc(C(F)(F)F)cc(C(F)(F)F)c3)cn2)CC1)N1CCN(C2CCC2)CC1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 6/20 0.52
ALDH1A1 P00352 3/20 0.52
MAPT P10636 2/20 0.52
MEN1 O00255 1/20 0.52
KMT2A Q03164 1/20 0.52
NPSR1 Q6W5P4 1/20 0.52
HRH3 Q9Y5N1 2/20 0.39
HSD11B1 P28845 2/20 0.39
CHRM4 P08173 1/20 0.38
HPGD P15428 1/20 0.38
DRD2 P14416 1/20 0.38
DRD3 P35462 1/20 0.38
POLB P06746 2/20 0.37
IDE P14735 1/20 0.37
TIPARP Q7Z3E1 2/20 0.37
CYP11B1 P15538 1/20 0.37
CYP11B2 P19099 1/20 0.37
KDM4E B2RXH2 2/20 0.37
LMNA P02545 1/20 0.37
THRB P10828 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3774025 0.91 MEN1 (0.48) SMN1; SMN2ALDH1A1MAPTMEN1KMT2A
SCHEMBL3764966 0.91 SMN1; SMN2 (0.47) SMN1; SMN2ALDH1A1MAPTMEN1KMT2A
SCHEMBL3767924 0.88 HRH3 (0.46) SMN1; SMN2ALDH1A1MAPTMEN1KMT2A
SCHEMBL3774094 0.86 MEN1 (0.42) SMN1; SMN2ALDH1A1MAPTMEN1KMT2A
SCHEMBL3776927 0.86 SMO (0.42) SMN1; SMN2ALDH1A1MAPTMEN1KMT2A
SCHEMBL3776065 0.85 MEN1 (0.47) SMN1; SMN2ALDH1A1MAPTMEN1KMT2A
SCHEMBL3775676 0.85 MAPT (0.47) SMN1; SMN2ALDH1A1MAPTMEN1KMT2A
SCHEMBL3771213 0.85 SMN1; SMN2 (0.52) SMN1; SMN2ALDH1A1MAPTMEN1KMT2A
SCHEMBL3769085 0.84 HRH3 (0.50) SMN1; SMN2ALDH1A1MAPTHRH3CYP11B1
SCHEMBL3763022 0.84 ALDH1A1 (0.46) ALDH1A1MAPTNPSR1HRH3KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7851474-B2 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION (US) 2010-12-14 US disclosed
US-7851474-B2 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION (US) 2010-12-14 US disclosed
US-20070049571-A1 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION 2007-03-01 US disclosed
US-20070049571-A1 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION 2007-03-01 US disclosed
WO-2007016496-A2 DIPIPERAZINYL KETONES AND RELATED ANALOGUES NEUROGEN CORPORATION (US) 2007-02-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070049571-A1 Dipiperazinyl ketones and related analogues HRH4, HRH3, HRH1 SMN1; SMN2 4282/4885ALDH1A1 1210/4885MAPT 1475/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.